Novavax (NVAX) Gross Profit Growth (3y) (2014 - 2026)

Novavax (NVAX) Gross Profit Growth (3y) (2014 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Profit Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 54.36%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 7.16%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 3.86%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 79.18%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Novavax 1.23 Bn 440.77 Mn 108.82 Mn 32.42%

Historic Data

Download Data
DateValue
Mar 31, 2026 32.42%
Dec 31, 2025 -10.71%
Sep 30, 2025 -45.36%
Jun 30, 2025 57.07%
Mar 31, 2025 -1.78%
Dec 31, 2024 -38.52%
Sep 30, 2024 -48.88%
Jun 30, 2024 7.40%
Mar 31, 2024 -57.37%
Sep 30, 2015 25.16%
Jun 30, 2015 78.60%
Mar 31, 2015 105.40%
Jun 30, 2014 21.27%
Mar 31, 2014 108.35%